Cresco Labs (CSE: CL) announced that they will be reporting their first quarter financials before market open on March 27th. Analysts have a consensus C$23.36 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating, 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$34 price target, and the lowest target comes from Echelon Wealth with a C$19 price target.
Fourteen analysts have revenue estimates for the third fiscal quarter. The mean between all 14 is U$211.76 million; this number has been revised upwards from U$209.46 million at the start of the year. The highest revenue estimate currently sits at $223 million, while the lowest comes in at a U$193 million estimate.
Eigtht analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 53.05%, with this number being revised slightly higher from 49.55% at the start of the year. Street high goes to BTIG with a 56% estimate and the lowest sits at 50% from Echelon.
Onto EBITDA estimates, there are currently 11 analysts who have third quarter EBITDA estimates. The mean is currently U$64.75 million, with this number being revised downwards from U$69.63 million at the start of the year. Street high goes to Haywood with a U$73.90 million EBITDA estimate and the lowest being from Echelon Wealth with a U$56.90 million estimate..
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
